Long-term outcomes of patients with unfavorable stage I–II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation

References

• Network NCC. Hodgkin lymphoma (version 1); 2017; [cited 2017 Nov 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
   Google Scholar
• Fermé C, Thomas J, Brice P, et al. ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin lymphoma with risk factors: results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer. 2017;81:45–55.
   PubMed Web of Science ®Google Scholar
• Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–4206.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–913.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Williams J, Bartlett NL, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol. 2000;18(5):972–980.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–637.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hoppe RT, Maeda LS, et al. Stage I–IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys. 2011;81(5):1374–1379.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013;24(4):1044–1048.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684–691.
   PubMed Web of Science ®Google Scholar
• Advani RH, Hong F, Fisher RI, et al. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol. 2015;33(17):1936–1942.
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862.
   PubMed Web of Science ®Google Scholar
• Sasse S, Brockelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 2017;35(18):1999–2007.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin lymphoma: long-term follow up of the German Hodgkin Study Group (GHSG) HD14 Trial. Washington (DC): American Society of Hematology; 2019.
   Google Scholar
• Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234–4242.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 populations); 1975; [cited 2012 Sep 7]. Available from: https://seer.cancer.gov/csr/1975_2017/
   Google Scholar
• Lagerlof I, Holte H, Glimelius I, et al. No excess long-term mortality in stage I–IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. 2020;188(5):685–691.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132(10):1013–1021.
   PubMed Web of Science ®Google Scholar